Immuno-oncology
Conference Coverage
Combo elicits lasting responses in metastatic melanoma
NATIONAL HARBOR, MD. – In a phase 1/2 trial of previously untreated advanced melanoma patients, the combination of bempegaldesleukin and nivolumab...
From the Journals
Atezolizumab/bevacizumab may offer benefit to patients with RCC
The combination performed better in renal cell carcinoma patients who were PD-L1 positive.
Conference Coverage
Neoantigen vaccine appears safe and active in NSCLC
NATIONAL HARBOR, MD. – The vaccine produced only grade 1 adverse events and yielded responses in 7 of 24 patients,...
Conference Coverage
Combo produces disappointing PFS, promising OS in metastatic colorectal cancer
NATIONAL HARBOR, MD. – Combination avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil failed to meet the primary endpoint for...
Conference Coverage
Armored CAR T cells elicit responses in NHL patients
NATIONAL HARBOR, MD. – ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, produced responses in 12 of 13 non-Hodgkin lymphoma...
Conference Coverage
Combo shows promise for checkpoint inhibitor-refractory urothelial carcinoma
NATIONAL HARBOR, MD – Combination sitravatinib and nivolumab produced responses in patients with checkpoint...
Conference Coverage
TLR9 agonist may overcome resistance to anti–PD-1 therapy in melanoma
NATIONAL HARBOR, MD. – CMP-001 plus pembrolizumab produced durable responses in patients who had progressed on prior...
Conference Coverage
Molecule exhibits activity in heavily pretreated, HER2-positive solid tumors
NATIONAL HARBOR, MD – In a phase 1 trial of 18 evaluable patients, PRS-343, a 4-1BB/HER2 bispecific molecule,...
From the Journals
Tumor surroundings may hold key to TNBC treatment optimization
Investigators say their retrospective study results demonstrate that each TNBC subtype is associated with specific tumor microenvironment profiles...
Conference Coverage
Better overall survival with nivolumab vs. chemo for advanced ESCC
BARCELONA –Nivolumab was associated with improved overall survival and a favorable safety profile vs. chemotherapy...
Conference Coverage
Nivolumab benefit for NSCLC persists at 5-year follow-up
BARCELONA – Nivolumab, compared with docetaxel chemotherapy, led to a fivefold improvement in 5-year overall...